abiraterone
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Amgen's portfolio. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Steroid 5-alpha-reductase inhibitor
pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
Amgen drug portfolio — 124 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
One Amgen Center Drive, Thousand Oaks, CA 91320, US HQ
1980 Founded
40,212 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
Amgen pipeline
Portfolio lens on 124 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Amgen drug portfolio — 124 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
abiraterone acetate
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Mechanism
- Cytochrome P450 17A1 inhibitor
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Adenosine receptor agonist
-
Development asset linked to Amgen in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Amgen's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
apremilast
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
asparaginase
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Asparagine.
- Target
- Asparagine
- Mechanism
- Asparagine hydrolytic enzyme
-
Development asset linked to Amgen in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
avacopan
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: C5a anaphylatoxin chemotactic receptor 1.
- Target
- C5a anaphylatoxin chemotactic receptor 1
- Mechanism
- C5a anaphylatoxin chemotactic receptor antagonist
-
azathioprine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
blinatumomab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- T cell surface glycoprotein CD3 cross-linking agent
-
cabazitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
carfilzomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Amgen in public FDA and regional records.
-
crisantaspase
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Amgen's portfolio. Molecular target: Asparagine.
- Target
- Asparagine
- Mechanism
- Asparagine hydrolytic enzyme
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
darbepoetin alfa
Blood and blood forming organs (B03)US regulatory status: approved. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
denosumab
Musculo-skeletal system (M05)US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.
- Target
- Tumor necrosis factor ligand superfamily member 11
- Mechanism
- Tumor necrosis factor ligand superfamily member 11 inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Amgen in public FDA and regional records.
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Amgen's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
epoetin alfa
Blood and blood forming organs (B03)US regulatory status: approved. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
erenumab
Nervous system (N02)Nervous system (N02) compound in Amgen's portfolio. Molecular target: Calcitonin gene-related peptide type 1 receptor.
- Target
- Calcitonin gene-related peptide type 1 receptor
- Mechanism
- Calcitonin gene-related peptide type 1 receptor antagonist
-
Development asset linked to Amgen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
etelcalcetide
Systemic hormonal preparations (H05)US regulatory status: approved. Molecular target: Extracellular calcium-sensing receptor.
- Target
- Extracellular calcium-sensing receptor
- Mechanism
- Calcium sensing receptor agonist
-
Development asset linked to Amgen in public FDA and regional records. Molecular target: Extracellular calcium-sensing receptor.
- Target
- Extracellular calcium-sensing receptor
- Mechanism
- Calcium sensing receptor agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
evolocumab
Cardiovascular system (C10)US regulatory status: approved. Molecular target: Proprotein convertase subtilisin/kexin type 9.
- Target
- Proprotein convertase subtilisin/kexin type 9
- Mechanism
- Subtilisin/kexin type 9 inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to Amgen in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
inebilizumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Amgen's portfolio. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- B-lymphocyte antigen CD19 binding agent
-
infliximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
irinotecan hydrochloride trihydrate
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Amgen's portfolio. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
levetiracetam
Nervous system (N03)US regulatory status: approved. Molecular target: Synaptic vesicle glycoprotein 2A.
- Target
- Synaptic vesicle glycoprotein 2A
- Mechanism
- Synaptic vesicle glycoprotein 2A modulator
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
mannitol
Respiratory system (R05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
mercaptopurine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).
- Target
- Inosine-5'-monophosphate dehydrogenase (IMPDH)
- Mechanism
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
-
mycophenolate mofetil
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).
- Target
- Inosine-5'-monophosphate dehydrogenase (IMPDH)
- Mechanism
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
ocrelizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
panitumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Amgen in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
pegaspargase
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Asparagine.
- Target
- Asparagine
- Mechanism
- Asparagine hydrolytic enzyme
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Amgen in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
regorafenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Discoidin domain-containing receptor 2.
- Target
- Discoidin domain-containing receptor 2
- Mechanism
- Fibroblast growth factor receptor 2 inhibitor
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
romiplostim
Blood and blood forming organs (B02)US regulatory status: approved. Molecular target: Thrombopoietin receptor.
- Target
- Thrombopoietin receptor
- Mechanism
- Thrombopoietin receptor agonist
-
romosozumab
Musculo-skeletal system (M05)Musculo-skeletal system (M05) compound in Amgen's portfolio. Molecular target: Sclerostin.
- Target
- Sclerostin
- Mechanism
- Sclerostin inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
siltuximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6.
- Target
- Interleukin-6
- Mechanism
- Interleukin-6 inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
sotorasib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: GTPase KRas.
- Target
- GTPase KRas
- Mechanism
- GTPase KRas inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved.
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
Development asset linked to Amgen in public FDA and regional records.
-
tarlatamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Amgen's portfolio. Molecular target: Delta-like protein 3.
- Target
- Delta-like protein 3
- Mechanism
- Delta-like protein 3 binding agent
-
Development asset linked to Amgen in public FDA and regional records.
-
tocilizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit inhibitor
-
Development asset linked to Amgen in public FDA and regional records.
-
trifluridine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Vasopressin receptor.
- Target
- Vasopressin receptor
- Mechanism
- Vasopressin receptor agonist
-
Development asset linked to Amgen in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Amgen in public FDA and regional records.